Indegene Limited reported strong financial growth for the financial year ending March 31, 2026. The company achieved consolidated revenue of ₹35,105 million and a profit after tax of ₹4,011 million. Following this performance, the Board of Directors has recommended a final dividend of ₹2.25 per equity share. The company also highlighted significant strategic acquisitions, including BioPharm Parent Holding, Inc., to further expand its healthcare marketing and transformation consulting capabilities.
Annual Financial Highlights
For the financial year ended March 31, 2026, Indegene Limited demonstrated sustained growth. Consolidated revenue from operations reached ₹35,105 million, up from ₹28,393 million in the previous year. The company recorded a profit after tax of ₹4,011 million. On a standalone basis, revenue was ₹12,206 million with a profit after tax of ₹2,119 million for the same period.
Dividend Recommendation
Recognizing the company’s strong performance, the Board of Directors has recommended a final dividend of ₹2.25 per equity share (face value of ₹2 each) for the 2026 fiscal year. This dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Strategic Acquisitions and Growth
The 2026 fiscal year was marked by key strategic moves to bolster service offerings. Notable acquisitions included BioPharm Parent Holding, Inc. for ₹8,821 million to enhance AI and digital advertising capabilities, Warn & Co Limited for specialized transformation consulting, and Cake Kommunikations Holdings GmbH to expand the company’s footprint in the European market.
Operational Reorganization
Effective October 1, 2025, the company successfully realigned its business segments by merging the Brand Activation segment into the Enterprise Commercial Solutions unit. The company now reports under two primary segments: Enterprise Commercial Solutions and Enterprise Medical Solutions, providing a more streamlined approach to meeting client needs in the life sciences sector.
Source: BSE
